Evidence map›Paper›PMID 41992035›Full record

ArticleScientific reports2026

Role of tumor markers before or during chemotherapy for digestive neuroendocrine carcinomas as an exploratory analysis of JCOG1213.

Tomoyuki Satake, Chigusa Morizane, Nozomu Machida, Yoshitaka Honma, Takuji Okusaka, Narikazu Boku, Ken Kato, Gakuto Ogawa, Yusuke Sano, Hiroshi Imaoka and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Tomoyuki SatakeNational Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Chiba, Japan. tosatake@east.ncc.go.jp.
Chigusa MorizaneNational Cancer Center Hospital, Tokyo, Japan.
Nozomu MachidaDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Yoshitaka HonmaNational Cancer Center Hospital, Tokyo, Japan.
Takuji OkusakaNational Cancer Center Hospital, Tokyo, Japan.
Narikazu BokuNational Cancer Center Hospital, Tokyo, Japan.
Ken KatoNational Cancer Center Hospital, Tokyo, Japan.
Gakuto OgawaJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Yusuke SanoJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Hiroshi ImaokaNational Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Chiba, Japan.
Satoshi KobayashiDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Takeshi TerashimaDepartment of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
Masafumi IkedaNational Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Chiba, Japan.
Naohiro OkanoKyorin University Faculty of Medicine, Mitaka, Japan.
Kensei YamaguchiCancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Takuji SatoKochi Health Sciences Center, Kochi, Japan.
Nobumasa MizunoAichi Cancer Center Hospital, Nagoya, Japan.
Yuko KitagawaKeio University School of Medicine, Tokyo, Japan.
Masanori TerashimaShizuoka Cancer Center, Shizuoka, Japan.
Makoto UenoDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical utility of tumor markers such as neuron-specific enolase (NSE) and progastrin-releasing peptide (ProGRP) in digestive neuroendocrine carcinoma (NEC) remains unclear. This exploratory analysis aimed to evaluate whether pretreatment and changes of tumor marker levels can predict treatment efficacy. In 137 of the 170 patients enrolled in JCOG1213 with digestive NECs (WHO 2010), we evaluated the association between treatment response and pretreatment NSE and ProGRP levels as well as the changes of these tumor markers from baseline to 6 weeks after chemotherapy. Pretreatment NSE and ProGRP were elevated in 127 and 74 patients. The objective response rate was 58.3%/55.6% in patients with high/normal NSE, and 60.8%/56.7% in patients with high/normal ProGRP. Any decline in tumor markers at 6 weeks tended to be associated with response, particularly for NSE than for ProGRP. The odds ratios for response in decreased NSE and ProGRP at 6 weeks of chemotherapy were 3.231 (P = 0.0198) and 1.652 (P = 0.2247) in multivariable analysis. Pretreatment NSE and ProGRP levels were not associated with tumor response. NSE and ProGRP have potential roles in treatment monitoring, especially changes in NSE were more relevant to tumor response than changes in ProGRP.

Indexed as

Biomarkers, TumorCarcinoma, NeuroendocrinePeptide FragmentsPhosphopyruvate HydrataseAgedFemaleHumansMaleMiddle AgedRecombinant ProteinsTreatment OutcomeBiomarkers, TumorPeptide FragmentsPhosphopyruvate Hydratasepro-gastrin-releasing peptide (31-98)Recombinant ProteinsNeuroendocrine carcinomaNeuron-specific enolaseProgastrin-releasing peptideTumor marker

Identifiers

PMID41992035
PMCPMC13243546

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.